Esophagogastric Adenocarcinoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | HER2-positive | Esophagogastric Adenocarcinoma | Capecitabine, Cisplatin, Trastuzumab | |
| Sensitivity (+) | HER2-positive | Esophagogastric Adenocarcinoma | Cisplatin, Fluorouracil, Trastuzumab | |
| Sensitivity (+) | ERBB2 amplification | Esophagogastric Adenocarcinoma | Capecitabine, Cisplatin, Trastuzumab | |
| Sensitivity (+) | ERBB2 amplification | Esophagogastric Adenocarcinoma | Cisplatin, Fluorouracil, Trastuzumab | |
| Sensitivity (+) | MSI-H | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| Sensitivity (+) | dMMR | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Fluorouracil, Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-negative, PD-L1 (CPS) >= 5 | Esophagogastric Adenocarcinoma | Nivolumab, Oxaliplatin | |
| Sensitivity (+) | HER2-positive | Esophagogastric Adenocarcinoma | Cisplatin, Fluorouracil, Trastuzumab |